Full Breakdown
Nourish Secures $100 Million Series C to Scale AI-Powered Metabolic Care
5/20/2026, 10:56:47 AM
Funding Milestone and Strategic Intent
On May 19 2026, Nourish, a virtual metabolic health clinic headquartered in New York, announced a $100 million Series C round, bringing total capital raised to $215 million and valuing the company at $1.75 billion. The round was led by Menlo Ventures and included Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak and Operator Partners. Menlo Ventures partner J.P. Sanday will join Nourish’s board. The capital will fund expansion of the clinical network, further development of proprietary AI agents, and deeper integration with health-plan, employer and health-system partners.
Clinical Model and AI Integration
Nourish operates a dietitian-led, virtual-first care model that pairs each patient with a Registered Dietitian (RD) for personalized nutrition counseling, lab testing, and, when clinically indicated, GLP-1 medication management. A patient-facing AI health agent embedded in the mobile app provides continuous behavior-change nudges and care coordination, while a provider-facing AI copilot automates documentation, prior-authorization workflows and real-time insight generation. The platform supports more than 10,000 RDs and serves patients in all 50 states through contracts with hundreds of health plans covering over 200 million lives.
Measurable Outcomes and Economic Impact
Company data report average clinical improvements of 8 % weight loss, a 1.3-point reduction in A1C for diabetic cohorts, a 31-point drop in LDL cholesterol and a 23-point decline in systolic blood pressure. These outcomes translate into estimated annual savings of more than $2,000 per patient for health plans. The model is positioned as a cost-containing alternative to reliance on GLP-1 drugs alone, which are expensive and exhibit low long-term adherence.
Market Context and Limitations of GLP-1 Monotherapy
Industry analysts note that the recent surge in GLP-1 prescriptions such as Ozempic and Wegovy has reshaped metabolic-health treatment but also introduced challenges: the drugs are costly, and fewer than half of patients remain on therapy after six months, often regaining lost weight without sustained lifestyle support. Nourish’s integrated approach seeks to address these gaps by embedding medication within a broader nutrition-first framework.
Official Statements
Nourish CEO Aidan Dewar said the funding will accelerate network growth, AI development and partnership depth, enabling the company to meet rising demand for scalable chronic-disease care. Menlo Ventures partner J.P. Sanday highlighted that Nourish uniquely combines a large dietitian network, deep payer relationships and proven clinical outcomes—three pillars rarely achieved together. The company also emphasized its goal to become the default venue for chronic-disease prevention and treatment.
Conflicting Reports & Gaps
Sources differ on the total annual U.S. healthcare expenditure attributed to chronic disease, citing “nearly $5 trillion” and “90 % of $4.9 trillion.” Both figures underscore the magnitude of the problem but reflect slight variation in reported totals. No independent outcome data beyond company-provided metrics are available in the sources.
Verbatim Quotes
- “Chronic disease is the largest cost driver in U.S. healthcare, and the system still isn't built to treat it,” — Aidan Dewar, Co-Founder & CEO, Nourish
- “Too often, patients get expensive, reactive, fragmented care that doesn’t actually make them healthier.” — Aidan Dewar
- “Chronic disease is the central failure of U.S. healthcare — nearly 200 million Americans affected, trillions spent, and outcomes that still don’t move. What Nourish has built in four years is remarkable: a care model that actually bends the cost curve, with 10,000 dietitians, deep payer relationships, and clinical outcomes patients stick with,” — J.P. Sanday, Partner, Menlo Ventures
- “What Nourish has built in four years is remarkable: a care model that actually bends the cost curve, with 10,000 dietitians, deep payer relationships, and clinical outcomes patients stick with.” — J.P. Sanday
- “Sanday, Partner at Menlo Ventures, summarized the thesis clearly: most startups succeed in scaling a network, building an enterprise sales pipeline, or proving clinical outcomes, but very few achieve all three simultaneously.” — J.P. Sanday
- “Chronic disease is the biggest cost burden in U.S. healthcare, yet patients still receive fragmented, reactive care,” — Aidan Dewar
What’s Next
Nourish plans to leverage the Series C capital to broaden AI capabilities, increase RD recruitment, and solidify contracts with additional health plans and employers. The company aims to expand its GLP-1 integration while scaling the virtual clinic to meet projected growth in demand for comprehensive metabolic-health solutions.
